Five-year efficacy and safety of tildrakizumab in patients with moderate-to-severe psoriasis who respond at week 28: pooled analyses of two randomized phase III clinical trials (reSURFACE 1 and reSURFACE 2).

D ThaciStefano PiasericoR B WarrenAditya Kumar GuptaW CantrellZ DraelosP FoleyA IgarashiR G LangleyA AsahinaM YoungM FalquésI Pau-CharlesA M MendelsohnS J RozzoKristian Reich

Published in: The British journal of dermatology (2021)

TIL treatment provided sustained disease control over 5 years in week 28 TIL responders and ETN partial responders/nonresponders, with a reassuring safety profile.

Keyphrases

phase iii
placebo controlled
clinical trial
double blind
open label
phase ii
study protocol
early onset
high intensity
randomized controlled trial
replacement therapy